JSL
CTKB icon

JT Stratford LLC’s Cytek Biosciences CTKB Stock Holding History

JT Stratford LLC’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-36,670
Closed -$147K – 306
2025
Q1 		$147K Buy
+36,670
New +$190K 0.03% 275

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

JT Stratford LLC's CTKB Position: Q2 2025 in Review

JT Stratford LLC sold out of Cytek Biosciences (CTKB) in Q2 2025, closing a stake of 36,670 shares — an estimated $147K sold.

JT Stratford LLC first reported a position in CTKB in Q1 2025 and held it in 1 quarter. The position peaked at $147K in Q1 2025. 158 funds tracked by Wall St. Rank hold CTKB as of Q2 2025.

  • JT Stratford LLC reported no remaining Cytek Biosciences position as of Q2 2025 after selling out during the quarter.
  • JT Stratford LLC sold 36,670 Cytek Biosciences shares in Q2 2025, an estimated $147K.
  • JT Stratford LLC first reported a position in Cytek Biosciences in Q1 2025 and held it in 1 quarter.
  • JT Stratford LLC's Cytek Biosciences position peaked at $147K in Q1 2025.
  • 158 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2025.

Based on JT Stratford LLC's 13F filing for Q2 2025, filed 13 Aug 2025.